Repository logo
 
Publication

Development and biological evaluation of API-ILs based on anti-bacterial and anti-fungal drugs

2013Conference object Open access
Simple item page
dc.contributor.authorFerraz, Ricardo
dc.contributor.authorBranco, Luís
dc.contributor.authorFernandes, Rúben
dc.contributor.authorPrudêncio, Cristina
dc.contributor.authorNoronha, João Paulo
dc.contributor.authorPetrovski, Zeljko
dc.date.accessioned2013-09-24T15:51:11Z
dc.date.available2013-09-24T15:51:11Z
dc.date.issued2013
dc.description.abstractIn recent years Ionic Liquids (ILs) are being applied in life sciences. ILs are being produce with active pharmaceutical drugs (API) as they can reduce polymorphism and drug solubility problems [1] Also ILs are being applied as a drug delivery device in innovative therapies What is appealing in ILs is the ILs building up platform, the counter-ion can be carefully chosen in order to avoid undesirable side effects or to give innovative therapies in which two active ions are paired. This work shows ILs based on ampicillin (an anti-bacterial agent) and ILs based on Amphotericin B. Also we show studies that indicate that ILs based on Ampicillin could reverse resistance in some bacteria. The ILs produced in this work were synthetized by the neutralization method described in Ferraz et. al. [2] Ampicillin anion was combined with the following organic cations 1-ethyl-3-methylimidazolium, [EMIM]; 1-hydroxy-ethyl-3-methylimidazolium, [C2OHMIM]; choline, [cholin]; tetraethylammonium, [TEA]; cetylpyridinium, [C16pyr] and trihexyltetradecylphosphonium, [P6,6,6,14]. Amphotericin B was combined with [C16pyr], [cholin] and 1-metohyethyl-3-methylimidazolium, [C3OMIM]. The ILs-APIs based on ampicillin[2] were tested against sensitive Gram-negative bacteria Escherichia coli ATCC 25922 and Klebsiella pneumonia (clinical isolated), as well as on Gram positive Staphylococcus Aureus ATCC 25923, Staphylococcus epidermidis and Enterococcus faecalis. The arising resistance developed by bacteria to antibiotics is a serious public health threat and needs new and urgent measures. We study the bacterial activity of these compounds against a panel of resistant bacteria (clinical isolated strains): E. coli CTX M9, E. coli TEM CTX M9, E. coli TEM1, E. coli CTX M2, E. coli AmpC Mox2. In this work we demonstrate that is possible to produce ILs from anti-bacterial and anti-fungal compounds. We show here that the new ILs can reverse the bacteria resistance. With the careful choice of the organic cation, it is possible to create important biological and physic-chemical properties. This work also shows that the ion-pair is fundamental in ampicillin mechanism of action.por
dc.identifier.urihttp://hdl.handle.net/10400.22/2010
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherInstituto Politécnico do Porto. Escola Superior de Tecnologia da Saúde do Portopor
dc.publisherUniversidade Nova de Lisboa. Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa
dc.publisherUniversidade do Porto. Faculdade de Medicina da Universidade do Porto
dc.titleDevelopment and biological evaluation of API-ILs based on anti-bacterial and anti-fungal drugspor
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferencePlaceVilamoura, Portugalpor
oaire.citation.title5 Congress on Ionic Liquids, COIL-5por
person.familyNameFerraz
person.familyNameFernandes
person.familyNamePrudêncio
person.givenNameRicardo
person.givenNameRúben
person.givenNameCristina
person.identifier635792
person.identifier1200571
person.identifier.ciencia-id001E-71CE-F92D
person.identifier.ciencia-id0D1F-4090-E82A
person.identifier.ciencia-idC81E-F4EE-FADE
person.identifier.orcid0000-0002-1761-117X
person.identifier.orcid0000-0001-8933-3984
person.identifier.orcid0000-0002-9920-936X
person.identifier.ridG-5639-2011
person.identifier.scopus-author-id24464208500
person.identifier.scopus-author-id57640135700
person.identifier.scopus-author-id6508057930
rcaap.rightsopenAccesspor
rcaap.typeconferenceObjectpor
relation.isAuthorOfPublicationa5a8faa7-12a5-4b1c-bced-44c895677397
relation.isAuthorOfPublication9e6c397c-62d8-4a40-8ec7-ad05ae0ebcc4
relation.isAuthorOfPublication881a8ad5-ab13-4e49-89f4-08ca61cc81e3
relation.isAuthorOfPublication.latestForDiscoverya5a8faa7-12a5-4b1c-bced-44c895677397

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
POS_RicardoFerraz_2013.pdf
Size:
344.75 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESS - CQB - Posters apresentados em eventos científicos